Navigating Nitrosamine Impurities In Pharmaceutical Drug Development

The discovery of nitrosamine impurities in 2018 fundamentally shifted the pharmaceutical landscape, moving risk assessment from a technical afterthought to a core regulatory priority. Today, managing these potential carcinogens requires more than reactive testing; it demands an integrated strategy woven into the entire development life cycle. Identifying risks during early-stage chemistry—such as the presence of secondary amines or residual nitrites in excipients—provides the necessary flexibility to adjust route selection or salt forms before processes are locked.

Regulatory expectations have also matured, transitioning from uniform stringency to the Carcinogenic Potency Categorization Approach (CPCA), which scales oversight based on molecular structure and DNA reactivity. By combining robust vendor qualification with advanced analytical capabilities, developers can maintain both patient safety and product performance.